Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 nov 2015 - 18:39
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares
Bericht
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares
HALLE/SAALE, Germany, 5 November 2015 - Probiodrug AG (the "Company") (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today that it has priced 676,589 new shares, with a notional par value of EUR 1.00 per share, issued through a private placement, at an aggregate value of EUR 13.5 million. As a result, the management board of the Company has resolved, with approval of the Company's supervisory board, to increase its share capital by EUR 676,589, from EUR 6,765,898 to EUR 7,442,487, by issuing 676,589 new shares with a notional par value of EUR 1.00 per share.
Datum laatste update: 13 november 2024